The European Society for Medical Oncology will hold their annual Congress in Madrid, Spain, on September 8-12 this year. The three presentations that will discuss ROS1 specifically are listed below (you can see the complete abstracts by clicking on the presentation title).
1308PD – Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC). Lorlatinib showed clinical activity in ROS1+ NSCLC patients, a majority of whom had central nervous system involvement and most of whom had received prior crizotinib. Overall, lorlatinib was well-tolerated.
1362P – Safety and clinical activity of DS-6051b, a ROS1/NTRK inhibitor, in Japanese patients with NSCLC harboring ROS1 fusion gene. DS-6051b is well tolerated in Japanese patients with ROS-rearranged non-small cell lung cancer, and more effective in patients who have not taken crizotinib. The maximum tolerated dose was set at 600mg twice daily.